Compound Screening TRIZ Cases

Identify therapeutic compounds by purifying highly invasive fibroblasts using specific cell surface markers.

Inhibiting ADAMTS6 reduces MMP13 activity, preventing cartilage degradation and enabling regeneration.

A baculovirus binding assay measures therapeutic antibody interactions to calculate a BV score.

HDAC1/2 activators accelerate remyelination to address neuronal loss when immune suppression fails.

Identifying Syndecans as Rspondin receptors clarifies Wnt pathway mechanisms, enabling targeted therapeutic modulator screening.

An orthophosphoric acid coated cell membrane array reduces non-specific binding to improve measurement precision during GPCR-G protein interaction analysis.

Segmented luciferase-based screening identifies HSD17B inhibitors to address the lack of effective treatments for alcoholic and nonalcoholic liver diseases.

A SEDI antibody binds misfolded or monomeric SOD1 forms to enable specific detection of amyotrophic lateral sclerosis.

Environment-sensitive fluorescent compounds accumulate inside bacterial cells to provide direct optical signals of membrane permeability.

A gold nanoparticle-based peptide chip amplifies secondary ion mass spectrometry signals through a self-assembled monolayer structure.

Acid treatment dissociates antigen-antibody complexes, resolving measurement interference and enabling accurate potency testing in combination vaccines.

Three-dimensional muscle chips replicate complex biological interactions, enabling efficient identification of compounds that modulate contractile functions.

Isogenic human iPSC-derived cardiomyocytes replace animal models to resolve physiological differences and enable precise phenotypic attribution.

Segmented AR variants lacking ligand-binding domains drive constitutive signaling, bypassing hormone suppression to cause castration-resistant prostate cancer.

Genetically encoded biosensors detect intracellular voltage and ion changes in human cell models.

Deriving template molecules with functional groups screens protein libraries to identify novel bridging agents without prior structural knowledge.

Antisecretory factor protein normalizes interstitial pressure via NKCC1 regulation, resolving poor anticancer drug delivery in tumors.

Screening compounds against membrane steroid transporters identifies selective modulators of hormone signaling pathways.

Antibody-mediated conformational locking exposes occluded protein sites, enabling detection of small molecule binders that traditional native screening misses.

Modulators targeting the RIPK1 hydrophobic pocket overcome metabolic stability limitations of necrostatins while maintaining potent necroptosis inhibition.

Antigen-binding molecules recycle via histidine-mediated pH dissociation to extend plasma retention and neutralization duration.

Measuring PD-L1 isoform levels in biological samples enables precise identification of head, neck, and lung cancers.

Distinct fluorescent and luminescent markers differentiate cytostatic from cytotoxic responses in co-cultures.

An in vitro process determines IL-17 pro-inflammatory dependent level using intermediary target cells incubated with biological samples.

Segmented renal cell cultures predict in vivo responses to reduce development costs and time.

Inhibitory nucleic acids target aging pathways to treat disorders while simplifying therapeutic delivery.

Specific compounds bind amino acid residues at the nicotinamide inhibition site to overcome enzyme suppression and restore Sir2 functionality.

Liquid chromatography-tandem mass spectrometry enables synchronous detection of renin activity and influencing medications.

Acamprosate modulates ERK1/2, BDNF, and sAPP biomarkers to stratify heterogeneous ASD and FXS populations into distinct subgroups for targeted therapy.

Enhancing insulin receptor signaling accelerates clearance of toxic amyloid beta assemblies, addressing synaptic failure in Alzheimer's disease.

Continuous concentration gradients in a microfluidic chip eliminate discrete dilution steps, reducing reagent consumption while improving measurement precision.

Targeting Nkd2 protein expression reduces fibrosis and preserves kidney function without invasive dialysis or transplantation procedures.

Assess epithelial and mesenchymal biomarkers to determine tumor cell sensitivity to IGF-1R kinase inhibitors.

A 3D human liver organ model constructs spheroids in micropores using a collagen matrix to enhance hepatotoxic drug sensitivity.

Anti-EPO antibodies and siRNA block S1P pathways, inducing apoptosis in cancer stem cells.

Multi-stage selection of targeted complementarity determining region libraries captures cooperative mutations for optimized protein variants.

Positive allosteric modulators enhance orthosteric agonist binding affinity at mu opioid receptors, reducing tolerance and dependence.

RARRES1 knockout animal model measures CDK1-Cyclin B1 binding levels to screen cancer therapeutic agents, resolving late metastasis detection.

Function recovery after chemobleaching assay measures membrane protein surface repopulation rates using fluorescence intensity changes.

Oligonucleotides suppress MST3 expression to reduce intracellular cholesteryl ester, resolving identification gaps for metabolic disease treatments.

An acidic solution deactivates the enzyme while detecting urea, eliminating HPLC complexity and reducing reagent volume.

Engineered bacteriophage recognition elements expand host range for DNA transduction, overcoming narrow specificity limits in antibiotic-resistant strains.

Interleukin 24 binds Sigma 1 Receptors to induce apoptosis, clarifying the tumor-specific mechanism for targeted therapy.

Detecting THSD7A antibodies in blood resolves the lack of reliable tumor antigens by using immune proxies to diagnose cancer and membranous nephropathy.

Screening methods identify small molecule compounds to promote or inhibit circulating tumor cell proliferation.

HPSEC selection of macrocyclic peptides with non-canonical amino acids resolves the trade-off between structural diversity and screen complexity.

Human neonatal brown adipose stem cells differentiate on specialized scaffolds to support metabolic regulation.

Selective T2R antagonists reduce plant protein bitterness without dulling the overall taste experience.

Identified genetic loci guide screening assays to resolve residual symptom persistence in schizophrenia treatments.

Engineered cytochrome P450 monooxygenases remove alkyl ethers from peralkylated monosaccharide derivatives under mild aqueous conditions.